Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low ris...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Udgivet i:	Hum Vaccin Immunother
Main Authors:	Petry, Karl-Ulrich, Bollaerts, Kaatje, Bonanni, Paolo, Stanley, Margaret, Drury, Rosybel, Joura, Elmar, Kjaer, Susanne K., Meijer, Chris J. L. M., Riethmuller, Didier, Soubeyrand, Benoit, Van Damme, Pierre, Bosch, Xavier
Format:	Artigo
Sprog:	Inglês
Udgivet:	Taylor & Francis 2018
Fag:	Research Paper
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6067852/ https://ncbi.nlm.nih.gov/pubmed/29553886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1450125
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Lignende værker